TD Cowen notes Vyvgart’s $790M in Q1 net sales beat consensus and firm’s estimate despite expected, typical Q1 seasonality and unexpected and more pronounced Part D redesign headwinds. Management are confident sales will continue their solid growth in Q2 as “volume growth was robust in Q1 and misunderstood by investors,” according to the analyst, who views the selloff as a buying opportunity given the “robust trends.” The firm keeps a Buy rating and $761 price target on Argenx (ARGX) shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target lowered to $1,065 from $1,100 at Guggenheim
- Buy Recommendation for Argenx: Strong Vyvgart Sales Growth and Promising PFS Launch Drive Confidence
- Argenx price target raised to $803 from $796 at Citi
- Argenx Reports Strong Q1 2025 Financial Performance
- Argenx Se: Strong Sales and Financial Performance Reinforce Buy Rating Amid Stock Selloff